Company: PMVP
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030414
Chunk: 237

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 8
Chunk 237
---
 31, 2024 and 2023, the Company had reserved shares of common stock for issuance as follows: 

        December 31,

        2024

        2023

        Options issued and outstanding

        8,653,913

        6,973,464

        Shares available for future stock option and RSU grants

        5,321,104

        4,474,411

        Shares available for employee stock purchase plan

        1,408,321

        1,056,832

        Total

        15,383,338

        12,504,707

      ATM ProgramOn October 4, 2021, the Company entered into an at-the-market offering program (the “ATM Program”) pursuant to which, the Company may offer and sell shares of its common stock having aggregate gross sales proceeds of up to $150.0 million from time to time. As of December 31, 2024, the Company had approximately $113.8 million remaining in gross proceeds available for future issuances of common stock under the ATM Program.

8.   Stock Plan2020 Equity Incentive PlanThe 2020 Equity Incentive Plan (the “2020 Plan”) was approved by the Company’s  board of directors on September 24, 2020.  The 2020 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company’s officers, employees, directors and consultants. The number of shares of common stock initially reserved for issuance under the 2020 Plan was 4,406,374, which shall be increased, upon approval by the Company’s  board of directors, on January 1, 2021 and each January 1 thereafter, in an amount equal to the least of (i) 4,406,374 shares of common stock, (ii) five percent (5%) of the outstanding common stock on the immediately preceding December 31, or (iii) such number of common stock determined by the board of directors no later than the immediately preceding December 31.  For 2022, the board’s compensation committee, as the 2020 Plan administrator, exercised its discretion under clause (iii) to increase the number of shares of common stock reserved for issuance under the 2020 Plan by a lesser amount of